DeepHealth (formerly Kheiron Medical Technologies)

by DeepHealth (formerly Kheiron Medical Technologies)  · Based in United States → — Empowering breakthroughs in care through imaging.
Oncology Radiology Women's Health
Website Demo Contact
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

DeepHealth, formerly Kheiron Medical Technologies, is an AI-powered health informatics company that develops solutions for diagnostic imaging. It is a wholly-owned subsidiary of RadNet, Inc.

DeepHealth’s portfolio includes AI-powered solutions across several specialties, including breast, prostate, chest, neuro, and thyroid health. These solutions are designed for radiologists and other healthcare professionals in various care settings, particularly those involved in large-scale diagnostic and screening programs.

The company’s offerings, such as the SmartMammo™ Breast Suite, integrate into existing diagnostic workflows, aiming to enhance diagnostic accuracy and workflow efficiency. For example, the Breast Suite includes AI-powered cancer detection, automated density assessment, and risk assessment, with capabilities to incorporate prior exams for comparison. DeepHealth also offers enterprise imaging solutions like the Diagnostic Suite™, which provides PACS functionality and advanced image management, and the Operations Suite™, which includes RIS functionality and real-time workflow management.

Notable capabilities include AI-assisted nodule detection in chest CT scans and the identification of breast arterial calcifications (BACs) on mammograms. DeepHealth’s cloud-native operating system, DeepHealth OS, aims to unify data across clinical and operational workflows and provide personalized AI-powered experiences.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered breast cancer detection
  • Supports radiologists in decision-making
  • Functions as independent reader
  • Functions as concurrent reader
  • Triage tool for breast screening
  • Enhanced workflow efficiency
  • Improved diagnostic accuracy
  • Seamless integration into existing workflows

Use Cases

  • Breast cancer screening programs
  • Radiologist support in mammography interpretation
  • Optimizing diagnostic workflows
  • Large-scale diagnostic and screening programs

What Physicians Need to Know

Evidence Base
MIA (Mammography Intelligent Assessment) is built upon a foundation of extensive deep learning research and clinical studies focused on mammography analysis. It leverages large datasets of mammograms to learn patterns associated with breast cancer.
Clinical Validation Studies
MIA has undergone rigorous clinical validation. Studies have demonstrated its ability to detect breast cancer with comparable or superior accuracy to human radiologists, particularly in identifying subtle cancers that might be missed. Key studies include those published in Nature Medicine and other peer-reviewed journals, showcasing its performance across diverse populations and mammography types.
Alert Fatigue Management
MIA is designed to be a supportive tool, not an overwhelming one. It highlights areas of concern on mammograms, allowing radiologists to focus their attention efficiently rather than generating numerous low-value alerts. The system aims to reduce the cognitive load by pre-screening and prioritizing.
Clinical Workflow Integration
MIA is designed for seamless integration into existing breast screening workflows. It can be incorporated into PACS (Picture Archiving and Communication Systems) to provide AI-powered insights directly within the radiologist's reading environment, minimizing disruption.
Decision Audit Trail
The system provides a clear audit trail of its analysis, indicating the regions of interest identified by the AI. This transparency allows radiologists to understand the basis of MIA's suggestions and supports their final diagnostic decisions.
Physician Tip

Utilize MIA as a 'second reader' to enhance confidence and potentially reduce recall rates. Pay close attention to areas flagged by MIA, especially in dense breast tissue. Integrate MIA's insights into your overall assessment, combining AI findings with patient history and other imaging modalities for a comprehensive diagnosis.

MIA is designed to integrate with standard PACS and reporting systems used in radiology departments, ensuring a smooth transition into existing clinical workflows without requiring significant changes to infrastructure.

Details

Category Clinical Decision Support & Reference, Population Health Analytics, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud-native (DeepHealth OS), AWS Marketplace, on-premise (interoperable with legacy PACS).
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology, Women's Health

Support & Reliability

What the Web Says

DeepHealth, formerly Kheiron Medical Technologies, develops AI-powered health informatics solutions, with a primary focus on breast cancer screening through its Miau00ae (Mammography Intelligent Assessment) AI tool. The company aims to improve cancer detection rates, reduce radiologist workload, and streamline the overall screening process. Recent studies and evaluations have shown Mia's potential to significantly increase early breast cancer detection and decrease unnecessary patient recalls.

Overall: Positive

Strengths

  • Increased breast cancer detection rates (up to 10-13% more than human-only review).
  • Reduced radiologist workload (by up to 30-36%).
  • Faster notification times for patients (from two weeks to three days).
  • Decreased unnecessary patient recalls and biopsies.
  • Early detection of high-grade and invasive cancers.
  • Cloud-native operating system that unifies data and personalizes AI-powered workspaces.

Limitations

  • Potential for overdiagnosis, though the technology is still being researched.
  • Not allowed to learn on the job and evolve as it's used due to current health guidelines.
  • Concerns about technology compromising human expertise and patient trust in AI.
  • One study found an AI system missed nearly one-third of breast cancers, particularly in dense breast tissue.
  • Compensation and benefits for knowledge workers and doctors at parent company RadNet may not be competitive.
  • Some employee reviews for RadNet (DeepHealth's parent company) mention a stressful environment, low pay, and high turnover.

Based on reviews from: Doctors.net, Imperial News, Feel For Your Life, BBC News - YouTube, AI Knowledge Hub, University of Glasgow, Handshake, Deephealth Expands Its AI-Powered Cancer Diagnostic and Screening Portfolio with the Acquisition of Kheiron, DeepHealth - Radiology AI-Powered Health Informatics | RadNet, RadNet Manager (DeepHealth) Review: Kind of run like a mid-tier private equity firm, DeepHealth - 2026 Company Profile, Team, Funding & Competitors - Tracxn, DeepHealth Showcases AI Radiology Solutions at ECR 2025 : r/ArtificialNtelligence - Reddit, DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound, MedTech Innovator, DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite | RadNet Inc, Evidence - DeepHealth, About - DeepHealth, DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLiveu2122 : r/Quantisnow - Reddit, Real-world stories Archives - DeepHealth, Deephealth - Ketryx, Clinical and technical evidence | Artificial intelligence in mammography | Advice - NICE, Shocking Acquisition: Kheiron Medical, a Pioneer in AI Breast Cancer Detection, Acquired by RadNet and DeepHealth for Just $1 Million USD | by Amine Korchi MD | Medium, DeepHealth - BBC, ECR - DeepHealth, DeepHealth gets FDA nod for AI tool that reads ultrasounds, creates reports | MedTech Dive, DeepHealth | AuntMinnie, New Way Now: How DeepHealth shifts cancer detection to curative using Google Cloud, AI Misses Nearly One-Third of Breast Cancers, Study Finds - EMJ

Last updated: 2026-09-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DeepHealth (formerly Kheiron Medical Technologies)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

DeepHealth
DeepHealth Achieves Multiple Regulatory Milestones for Neuro, Prostate and LumbarMR
DeepHealth received CE Marking for its Neuro Suite (Brain Health and Brain Age solutions) and LumbarMR solution, along with FDA 510(k) clearance and CE Marking for its Prostate AI solution, expanding its portfolio of clinical AI solutions in radiology.
2026-05
DeepHealth
DeepHealth Expands Its AI-Powered Cancer Diagnostic and Screening Portfolio with the Acquisition of Kheiron
DeepHealth acquired Kheiron Medical Technologies Limited, a UK-based AI cancer diagnostic company specializing in deep learning solutions for breast cancer detection, to expand its AI-powered diagnostic and screening portfolio.
2024-10
Medical Device Network
FDA grants 510K clearance for DeepHealth's AI breast ultrasound technology
DeepHealth, a RadNet subsidiary, received FDA 510(k) clearance for its DeepHealth Breast Ultrasound, an AI-based tool designed to standardize, improve accuracy, and enhance efficiency in breast ultrasound imaging.
2026-08
RadNet Inc.
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
DeepHealth received FDA 510(k) clearances for Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro (now Mammo Dx), enhancing its AI-powered Breast Suite with cardiovascular insights and improved cancer detection capabilities.
2026-06
DeepHealth
Study Shows AI Can Bring Specialist-Level Breast Cancer Detection to More Patients
A study published in Radiology demonstrated that DeepHealth's AI-powered breast cancer screening workflow improved cancer detection rates among general radiologists, making their performance comparable to breast imaging specialists.
2026-07
DeepHealth
DeepHealth Expands Breast Suite with New FDA-Cleared AI Capabilities
DeepHealth received FDA 510(k) clearances for Breast Arterial Calcification Assessment and prior exam integration into ProFound Pro, now marketed as Mammo Dx, to enhance breast cancer detection and provide a more complete patient overview.
2026-06
GlobeNewswire
DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
DeepHealth announced FDA 510(k) clearance for DeepHealth Breast Ultrasound, an AI-powered solution designed to standardize, improve accuracy, and enhance efficiency in breast ultrasound imaging.
2026-07
DeepHealth
Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow
A Nature Health study, the largest real-world analysis of AI-driven breast cancer screening in the U.S., showed DeepHealth's AI-powered workflow increased cancer detection rates by 21.6% with equitable benefits across diverse patient populations.
2025-11

Videos

Product demos, reviews, and walkthroughs for DeepHealth (formerly Kheiron Medical Technologies).

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

DeepHealth's AI, Mia, is designed to integrate seamlessly with standard PACS systems, providing a 'second read' to support radiologists. It analyzes mammograms and highlights areas of suspicion, aiming to reduce reading times and improve accuracy without disrupting your current workflow.
Yes, DeepHealth's Mia is FDA cleared for use as an AI-enabled medical device for breast cancer screening. It also holds CE Mark certification, demonstrating compliance with European regulatory standards for medical devices.
Clinical studies have shown that DeepHealth's Mia can help detect cancers earlier and reduce the number of false positives, leading to improved patient outcomes and reduced recall rates. It acts as an independent reader, providing a consistent and objective assessment of mammograms.
While DeepHealth's AI is trained on diverse datasets, like all AI, it may have limitations in specific, underrepresented populations or extremely dense breast tissue. Continuous monitoring and updates are performed to address potential biases and improve performance across all patient demographics.
DeepHealth typically offers subscription-based pricing models, which can vary depending on the volume of studies and integration requirements. It's best to contact their sales team directly for a customized quote that aligns with your practice's specific needs and budget.
Several other AI solutions exist for breast cancer screening. DeepHealth differentiates itself through its extensive clinical validation, seamless integration capabilities, and a focus on providing a truly independent 'second read' to augment, rather than replace, radiologist expertise.
DeepHealth provides comprehensive training and ongoing support for physicians and their staff, including onboarding, technical assistance, and educational resources. This ensures smooth integration and optimal utilization of the AI solution within your clinical practice.

Compare DeepHealth (formerly Kheiron Medical Technologies)

VS
Transpara vs DeepHealth (formerly Kheiron Medical Technologies)
Clinical Decision Support & Reference Direct · 95/100
Transpara and DeepHealth (Mia) are highly comparable, both offering FDA-cleared AI solutions for breast cancer detection in mammography to enhance radiologist workflow. While Transpara emphasizes 2D and 3D…
VS
ChatGPT vs DeepHealth (formerly Kheiron Medical Technologies)
Clinical Decision Support & Reference Adjacent · 60/100
While both ChatGPT for Healthcare and DeepHealth's Mia offer AI-powered clinical decision support, their applications are distinct. ChatGPT for Healthcare provides a broad conversational AI for various clinical…
VS
DeepXray vs DeepHealth (formerly Kheiron Medical Technologies)
Clinical Decision Support & Reference Adjacent · 60/100
DeepXray and DeepHealth are both AI-powered radiology solutions, but they focus on different specialties. DeepXray specializes in detecting and monitoring osteoarthritis and osteoporosis using X-rays, while DeepHealth's Mia…
VS
BriefCase vs DeepHealth (formerly Kheiron Medical Technologies)
Clinical Decision Support & Reference Adjacent · 60/100
While both Aidoc's BriefCase and DeepHealth's Mia are AI-powered radiology tools, they serve different primary functions and specialize in distinct areas. BriefCase focuses on AI-driven communication and collaboration…

Related Tools

a2z Radiology AI Inc.
a2z Radiology AI Inc.
Clinical Decision Support & Reference
Abdo-Triage is an AI tool by a2z Radiology AI Inc. designed to assist radiologists in triaging abdominal imaging studies and identifying critical findings.
OpenAI
OpenAI
Clinical Decision Support & Reference
ChatGPT for Clinicians by OpenAI provides advanced AI capabilities to assist medical professionals with information synthesis, documentation, and patient communication.
Free for chatgpt for clinicians (for verified us clinicians); custom pricing for chatgpt for healthcare and api.
Perimeter Medical Imaging AI
Perimeter Medical Imaging AI
Clinical Decision Support & Reference
The Claire OCT System by Perimeter Medical Imaging AI uses Optical Coherence Tomography and AI to provide real-time, high-resolution tissue imaging during surgery to help identify cancerous tissue.
Veeva Link Medical Insights
Veeva Systems
Clinical Decision Support & Reference
Veeva Link Medical Insights streamlines the end-to-end process—from capture to action. It is a combination of applications, agents, and services for teams to easily capture insights related to KOLs in compliant free text, get relevant themes, and ask questions to improve decision-making.
Semantic Clinical Artificial Intelligence (SCAI)
University at Buffalo (UB)
Clinical Decision Support & Reference
Semantic Clinical Artificial Intelligence (SCAI) is a clinical AI tool developed by University at Buffalo researchers that can respond to medical questions, demonstrating high accuracy on medical licensing exams and augmenting physician decision-making.
Prenaital
Prenaital
Clinical Decision Support & Reference
Prenaital uses AI to detect and manage high-risk pregnancies, enhancing the detection of conditions like abnormal fetal growth, preterm birth, and stillbirth.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-07-03 | First Added: 2026-06-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.